BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biotechnology company focused on developing therapies for cancers driven by RAS and PI3Kα, two frequently mutated oncogenes ¹. The company's core business model revolves around the discovery, development, and potential commercialization of orally bioavailable small molecule inhibitors designed to achieve high levels of target inhibition against these oncogenic drivers while maintaining a favorable tolerability profile ². BBOT aims to generate revenue from product sales, though it does not anticipate this for several years, if ever ³. The company's primary customer segments are patients afflicted with metastatic cancer, specifically those with KRAS G12C, KRAS G12D, KRAS G12V, or PIK3CA mutations, and HER2 amplification ⁴.

BBOT's pipeline consists of three orally bioavailable small molecule inhibitors: BBO-8520, BBO-11818, and BBO-10203 ⁵. BBO-8520 is a direct KRAS G12C ON/OFF inhibitor, designed to engage both the GTP-bound active "ON" state and the GDP-bound inactive "OFF" state of the mutant protein ⁶. This mechanism is intended to provide significant benefit to patients with KRAS G12C-driven Non-Small Cell Lung Cancer (NSCLC) as monotherapy and in combination with other therapies ⁷. The ONKORAS-101 Phase 1 study is evaluating BBO-8520 alone and in combination with pembrolizumab in NSCLC patients with a KRAS G12C mutation ⁸. Preliminary clinical data from January 2026 showed a 65% (11/17) objective response rate (ORR) in NSCLC patients across all dose levels, including 10 partial responses (PRs) and one complete response (CR) ⁹. The safety profile was generally tolerable, with no dose-limiting toxicities, no Grade 3 or higher liver toxicity, and only low frequency and low grade, transient, and clinically asymptomatic liver enzyme elevations ¹⁰.

BBO-11818 is an orally bioavailable pan KRAS "ON/OFF" inhibitor, designed to bind directly to KRAS G12D, G12V, G12C, and WT KRAS with picomolar affinity ¹¹. It has shown low nanomolar potency in KRAS mutant cells with greater than 500-fold selectivity for KRAS over H- and NRAS ¹². The KONQUER-101 trial is an ongoing Phase 1 study evaluating BBO-11818 in heavily pretreated subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors ¹³. Preliminary monotherapy data as of December 10, 2025, showed encouraging anti-tumor activity, including a PR in a patient with pancreatic ductal adenocarcinoma (PDAC) with a 56% tumor reduction, which was subsequently confirmed ¹⁴. BBO-11818 monotherapy treatment (n=13) appeared generally tolerable with no dose-limiting toxicities, and treatment-related adverse events were largely gastrointestinal-related ¹⁵.

BBO-10203, the RAS:PI3Kα Breaker, is an oral drug candidate that targets the RAS-binding domain of PI3Kα, preventing its activation by HRAS, NRAS, and KRAS in tumors ¹⁶. This mechanism aims to inhibit PI3Kα signaling in tumors while avoiding hyperglycemia and hyperinsulinemia, a common side effect of other PI3Kα inhibitors ¹⁷. The BREAKER-101 Phase 1 study is evaluating BBO-10203 as monotherapy and in combination with trastuzumab, fulvestrant ± ribociclib, or FOLFOX + bevacizumab in patients with locally advanced or metastatic HER2+ breast cancer (BC), HR+/HER2- BC, and KRAS mutant colorectal cancer (CRC) ¹⁸. Preliminary clinical data from January 2026 showed a differentiated safety profile with no hyperglycemia observed ¹⁹. As of December 10, 2025, there were no dose-limiting toxicities, no Grade ≥3 treatment-related adverse events except for one incidence of asymptomatic hypokalemia, and no dose reductions or treatment-related serious adverse events ²⁰.

For the fiscal year ended December 31, 2025, BBOT reported net losses of $134.0 million, compared to $74.3 million for the year ended December 31, 2024 ²¹. As of December 31, 2025, the company had an accumulated deficit of $356.6 million ²². The company has not generated any revenue to date ²³. BBOT's expenses are expected to increase substantially as it continues research and development, initiates additional clinical trials, and seeks marketing approval for its product candidates ²⁴.

Significant operational developments during the period include the disclosure of encouraging updated clinical data for BBO-8520 in January 2026, showing a 65% ORR in NSCLC patients with KRAS G12C mutation ²⁵. BBO-8520 in combination with pembrolizumab showed promising efficacy in both first-line and previously treated NSCLC KRAS G12C patients, with a differentiated liver toxicity profile ²⁶. Preliminary clinical data for BBO-11818 as of December 10, 2025, demonstrated encouraging early anti-tumor activity, including a confirmed PR in a PDAC patient ²⁷. For BBO-10203, preliminary clinical data from January 2026 highlighted a differentiated safety profile with no hyperglycemia observed, and 500 mg QD was selected as the recommended dose for expansion ²⁸. The company also plans to initiate internal combinations with BBO-8520 and BBO-11818 this year ²⁹.

BBOT estimates that its existing cash, cash equivalents, and short-term marketable securities as of the date of the report will be sufficient to fund its operating expenses and capital expenditure requirements into early 2028 ³⁰. The company anticipates incurring significant and increasing expenses and operating losses for the foreseeable future as it advances its product candidates ³¹.

BBOT plans to initiate internal combinations of BBO-10203 with BBO-8520 and BBO-11818 this year ³². This strategy aims to co-inhibit both the MAPK and PI3Kα-AKT pathways simultaneously in patients with KRAS mutant tumors, leveraging BBO-10203's unique mechanism of action to block oncogenic signaling while avoiding hyperglycemia ³³. The fact that BBO-10203 has the potential to provide benefit and avoid hyperglycemia in wild-type PIK3CA settings is key to these combination approaches, as RAS and PIK3CA are rarely co-mutated in human cancer ³⁴.

The company expects to share additional clinical data from the ONKORAS-101 study (BBO-8520) in the second half of 2026 ³⁵. For BBO-11818, additional clinical data from the KONQUER-101 study are expected to be available in the second half of 2026 ³⁶. Additional data from the BREAKER-101 study (BBO-10203) are also expected to be available in the second half of 2026 ³⁷.

BBOT's strategy emphasizes maximizing target inhibition through novel mechanisms of action and precise inhibitor design ³⁸. This includes designing KRAS inhibitors that bind directly to the protein with high affinity, inhibiting both ON and OFF states, and highly selective PI3Kα inhibitors that exclusively block RAS-dependent signaling ³⁹. This selective mechanism for PI3Kα is intended to achieve high levels of inhibition of RAS-dependent PI3Kα signaling while minimizing side effects such as hyperglycemia ⁴⁰.

The company plans to develop BBO-8520 for NSCLC patients with KRAS G12C mutation across various disease settings, as monotherapy or in combination with immunotherapy and other internal pipeline candidates ⁴¹. BBO-11818 is primarily intended for KRAS G12D and KRAS G12V mutant NSCLC, CRC, and PDAC ⁴². Commercial opportunities for BBO-11818 in NSCLC include combinations with immune-oncology agents like pembrolizumab, with or without platinum-based chemotherapy regimens in the first line, and monotherapy or combination with BBO-10203 in second-line plus metastatic populations ⁴³. In CRC, opportunities include combinations with chemotherapy and bevacizumab in first-line populations, as well as monotherapy or combination with BBO-10203 or EGFR antibodies ⁴⁴. For PDAC, commercial opportunities include combinations with chemotherapy regimens, monotherapy, and combination with BBO-10203 ⁴⁵. BBO-10203 is being developed in hormone receptor-positive PIK3CA mutant breast cancer in combination with HR-directed therapies and CDK4/6 inhibitors, HER2-positive breast cancer in combination with HER2-directed biologics, and KRAS G12X NSCLC, CRC, and PDAC in combination with KRAS inhibitors ⁴⁶.

BBOT intends to retain significant development and commercial rights to its investigational products and, if marketing approval is obtained, to commercialize them on its own, or potentially with a partner, in the U.S. and other regions ⁴⁷. The company plans to build the necessary infrastructure and sales, marketing, and commercial product distribution capabilities for the U.S., and potentially other regions, following further advancement of its investigational products ⁴⁸.

BBOT's federal net operating loss (NOL) carryforwards of approximately $148.8 million and state NOL carryforwards of approximately $129.8 million as of December 31, 2025, may be limited in their ability to offset future taxable income due to U.S. tax law restrictions, including the 80% limitation for federal NOL carryforwards generated after December 31, 2017 ⁴⁹.

BBOT faces substantial risks, including its limited operating history, absence of approved products, and lack of revenue generation, making it difficult for investors to evaluate its likelihood of success ⁵⁰. The company has incurred significant net losses, totaling $134.0 million in 2025 and $74.3 million in 2024, with an accumulated deficit of $356.6 million as of December 31, 2025, and expects to continue incurring losses ⁵¹. BBOT will require additional capital to finance operations, and its inability to raise funds on acceptable terms could force delays or elimination of research and development programs ⁵². The success of its product candidates is highly dependent on successful and timely completion of preclinical and clinical development, obtaining regulatory approvals, and commercialization, which are lengthy, complex, and unpredictable processes ⁵³. Preclinical and early clinical trial outcomes may not predict later success, and product candidates may cause significant adverse events or toxicities, potentially preventing approval or market acceptance ⁵⁴. The company relies on third parties for manufacturing and clinical trials, increasing risks of insufficient supplies, delays, or unsatisfactory performance ⁵⁵. BBOT faces intense competition from companies with greater financial resources and expertise, which could lead to competitors commercializing products more successfully or earlier ⁵⁶. If approved, BBOT's products may face unfavorable third-party coverage and reimbursement practices, as well as pricing regulations, which could limit market acceptance and profitability ⁵⁷. The business entails significant product liability risk, and insufficient insurance coverage could have an adverse effect ⁵⁸. Regulatory approval in one jurisdiction does not guarantee approval in others, and post-marketing requirements and oversight are significant ⁵⁹. Changes in tax law, including limitations on net operating loss carryforwards, could adversely affect financial condition ⁶⁰. The company's internal computer systems and those of third parties are vulnerable to security incidents and data breaches, which could result in significant liabilities and operational disruptions ⁶¹. The use of new technologies like artificial intelligence may present cybersecurity, data privacy, intellectual property, and regulatory risks ⁶². BBOT's operations are vulnerable to interruptions from natural disasters, power loss, and other events beyond its control ⁶³. Intellectual property risks include challenges to patent validity, enforceability, and ownership, potential infringement claims by third parties, and the inability to obtain or maintain adequate patent protection or licenses on commercially reasonable terms ⁶⁴.

Management emphasizes BBOT's mission to transform the lives of patients with cancers driven by RAS and PI3Kα, aiming to deliver well-tolerated, safe medicines with greater efficacy ⁶⁵. The company's strategic priorities include accelerating scientific and medical breakthroughs, focusing on patients with RAS- and PI3Kα-driven malignancies, and leveraging deep expertise in small molecule targeted oncology to maximize target inhibition ⁶⁶. Management highlights two key approaches: designing KRAS inhibitors that bind directly to the protein with high affinity to inhibit both ON and OFF states, and designing highly selective PI3Kα inhibitors that exclusively block RAS-dependent signaling to inhibit RAS-driven PI3Kα tumorigenesis while preserving PI3Kα signaling directly activated by growth factor receptors ⁶⁷. The company plans to develop these inhibitors both as monotherapy and in combination to provide meaningful benefit to patients by safely delivering high-level inhibition of oncogenic signaling ⁶⁸. Management expects to share additional clinical data from the ONKORAS-101, BREAKER-101, and KONQUER-101 studies in the second half of 2026 ⁶⁹.